title: Relationship among neuropeptide Y, catecholamines and haemodynamics in congestive heart failure.
abstract: The relationship among neuropeptide Y (NPY), catecholamines and haemodynamics was assessed both at baseline and during inotropic intervention in patients with congestive heart failure. Eighteen patients with idiopathic dilated cardiomyopathy (left ventricular ejection fraction (LVEF) = 26 +/- 10%) underwent both right and left catheterization. Haemodynamic parameters were recorded at baseline and during dobutamine infusion. To measure norepinephrine (NE), epinephrine (E) (nmol.l-1: radioenzymatic assay) and NPY (pmol.l-1: immunoradiometric assay) plasma concentrations, blood samples were drawn from the femoral artery and from the coronary sinus, both at baseline and during dobutamine infusion. At baseline, NPY concentration were 2.15 +/- 0.97 pmol.l-1 in the femoral artery and 1.97 +/- 0.63 pmol.l-1 in the coronary sinus. Peripheral concentrations of NPY were, however, no different from those of patients without congestive heart failure: 2.4 +/- 2.7 pmol.l-1. Peripheral NE concentration was correlated to haemodynamic parameters: LVEF (r = -0.65; P less than 0.01), cardiac index (r = -0.54; P less than 0.05), LV end-diastolic pressure (r = +0.59; P less than 0.05), while peripheral NPY and E concentrations were not. Dobutamine improved haemodynamics, since cardiac index increased by 30% and LV end-diastolic pressure decreased by 40% (P less than 0.01). Peripheral NE concentration decreased from 6.48 +/- 4.5 to 4.82 +/- 2.69 nmol.l-1 (P less than 0.05) but there was no change in E (0.99 +/- 0.61 vs 1.04 +/- 0.74 nmol.l-1) or NPY concentrations (2.41 +/- 0.99 pmol.l-1). In the coronary sinus, neither NE nor NPY concentrations changed during dobutamine infusion.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Service de Cardiologie, Hopital Universitaire Henri Mondor, Créteil, France.
authors.forename: J L
authors.initials: JL
authors.lastname: Dubois-Randé
authors.forename: E
authors.initials: E
authors.lastname: Comoy
authors.forename: P
authors.initials: P
authors.lastname: Merlet
authors.forename: C
authors.initials: C
authors.lastname: Benvenuti
authors.forename: C
authors.initials: C
authors.lastname: Carville
authors.forename: L
authors.initials: L
authors.lastname: Hittinger
authors.forename: I
authors.initials: I
authors.lastname: Macquin-Mavier
authors.forename: C
authors.initials: C
authors.lastname: Bohuon
authors.forename: A
authors.initials: A
authors.lastname: Castaigne
mesh_terms: D000328:Adult; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy / Q000503:physiopathology; D002908:Chronic Disease; D003331:Coronary Vessels / Q000187:drug effects / Q000503:physiopathology; D004280:Dobutamine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000097:blood*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009478:Neuropeptide Y / Q000097:blood*; D009638:Norepinephrine / Q000097:blood*; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology
chemical_list: D009478:Neuropeptide Y; D004280:Dobutamine; D009638:Norepinephrine; D004837:Epinephrine